Search results
15 Life-Altering Moments In The Lives Of Cancer Survivors That Will Give You A New Perspective On...
BuzzFeed via Yahoo News· 3 days agoAnton Dobrea / Getty Images 9."I am 78 years old and at the age of 70, I was diagnosed with prostate...
This Weird Habit Is One of the Most Common Signs of Brain Cancer, According to Neurologists
Parade via Yahoo News· 4 days agoMina...tumors." But how? Even some of your habits may be a signal you have brain cancer. Dr. Lobbous...
Lantheus (LNTH) Gains 33.3% YTD: What's Driving the Stock?
Zacks· 5 days agoFree Report) witnessed strong momentum in the year-to-date period. Shares of the company have rallied 33.3% compared with 3.1% growth of the industry. With healthy fundamentals ...
AstraZeneca's Combination Cancer Drug For Advanced Breast Cancer Study Flunks Late-Stage Trial -...
Benzinga· 4 days agoThe study did not meet the dual primary endpoints of improvement in overall survival (OS) versus...
Jazz drug for tremor fails study; Radiopharma drug developer ITM swaps CEOs
BioPharma Dive via Yahoo Finance· 1 day agoA medicine Jazz acquired in 2019 missed the goal of a Phase 2 study. Elsewhere, Vanda rejected two...
AstraZeneca's (AZN) Truqap Misses Endpoints in TNBC Study
Zacks via Yahoo Finance· 4 days agoAstraZeneca's (AZN) phase III CAPItello-290 study evaluating Truqap plus chemotherapy in patients...
AI Enhances Readability of Cancer Information for Patients
Medscape· 6 days agoChatGPT improved the readability of cancer-related information on patient-facing websites, without...
With iOnctura and Yellowstone, Syncona adds two cancer biotechs to growing portfolio
FierceBiotech· 2 days agoSyncona has added two up-and-coming cancer companies to its portfolio, ensuring the biotechs are armed with a combined total of over $100 million in series A and B funds.
IgG4-Related Disease Affects Men More Often, More Severely
Medscape· 3 days agoA recent study highlighted sex-based differences in manifestations of IgG4-related disease.
FDA Expands Orphan Drug Designation for SurVaxM, I | Newswise
Newswise· 2 days agoBUFFALO, N.Y. — The U.S. Food and Drug Administration (FDA) has expanded orphan drug designation for SurVaxM, a brain cancer immunotherapy born in the labs of Roswell Park ...